334 filings
8-K
AGRX
Agile Therapeutics Inc
9 Apr 24
Results of Operations and Financial Condition
8:30am
10-K
2023 FY
AGRX
Agile Therapeutics Inc
Annual report
28 Mar 24
4:31pm
8-K
AGRX
Agile Therapeutics Inc
28 Mar 24
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
9:06am
8-K
AGRX
Agile Therapeutics Inc
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
8-K
AGRX
Agile Therapeutics Inc
14 Mar 24
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
4:45pm
424B5
1y11ujjq41 1w8cnp7
23 Feb 24
Prospectus supplement for primary offering
4:57pm
424B5
bunuynqqz0 9hg7
23 Feb 24
Prospectus supplement for primary offering
4:55pm
8-K
0fy6bmbrogx6w
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
0qk5em0uo49l8e
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
8-K
k1guiolvzutd
6 Dec 23
Other Events
8:00am
8-K
bpqadlho
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
xyjaufi5vgbj3w0lw
9 Nov 23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:15am
8-K
8mm2q
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
rcm29cr h6
28 Sep 23
Entry into a Material Definitive Agreement
4:50pm